Biotech Co.** (Symbol) | Pharma Co. (Symbol/Country) | Type/Product Area | Amount ($M) |
Terms/Details (Date)@ |
MODIFIED AGREEMENTS | ||||
Abgenix Inc. | Pfizer Inc. (NYSE:PFE) |
Exercise of option under 12/97 agreement to use Abgenix's XenoMouse technology to generate fully human antibodies against undisclosed antigen targets |
ND | Pfizer exercised an option for a third antigen target; Abgenix will use XenoMouse to generate fully human antibodies for Pfizer and could receive research, license fees and milestones, plus royalties; Pfizer is responsible for manufacturing, product development and marketing (11/99) |
Albany Molecular Research Inc. | DuPont Pharmaceuticals Co. (unit of E.I. DuPont de Nemours; NYSE: DD) |
Expansion of 5/98 collaboration on several drug development projects encompassing medicinal chemistry, chemical development and preparative separations |
8-10/year |
AMRI will increase manpower devoted to DuPont projects, with further stepped increases in scientific support scheduled throughout 2000 (11/99) |
Axys Pharmaceuticals Inc. |
Merck & Co. Inc. (NYSE: MRK) |
Extension of 11/96 collaboration on inhibitors of cathepsin K (cysteine protease) as therapies for osteoporosis |
ND | Agreement extended for the second time, until 11/00 (11/99) |
Parke-Davis Pharmaceutical Research Division of Warner-Lambert Co. (NYSE:WLA) | Amendment to 11/97 collaboration to find genes implicated in schizophrenia and bipolar disorder |
ND |
Axys will transfer to Parke-Davis its human genomics research in schizophrenia and bipolar disease; Axys will receive an up-front payment and will have no continuing obligations with respect to the program (11/99) | |
Aurora Biosciences Corp. |
Eli Lilly and Co. (NYSE: LLY) | Amendment to 9/97 agreement under which Lilly joined a syndicate to underwrite and gain access to Aurora's Ultra-High-Throughput Screening System (UHTSS) | ND | Companies agreed to refocus collaboration on Aurora's bioassay technology and subsystems and discontinue further development and delivery of Lilly's customized UHTSS (11/99) |
Aurora Biosciences Corp. |
Bristol-Myers Squibb Co. (NYSE:BMY) |
Expansion of 12/96 screening and assay-development collaboration that also includes access to Aurora's Ultra-High-Throughput Screening System |
ND |
BMS purchased an Aurora voltage ion probe reader (VIPR) subsystem to extend the use of Aurora's ion channel technology platform; voltage sensing probes were licensed to BMS as part of original 12/96 agreement (11/99) |
Corvas International Inc. |
Schering-Plough Corp. (NYSE: SGP) |
Extension of 1994 collaboration for oral anti-coagulants based on inhibitors of key protease enzymes in the blood-clotting process |
3 |
Schering-Plough will continue to support preclinical development through 12/00, resulting in additional payments of $3M (12/99) |
Cubist Pharmaceuticals Inc. | Merck & Co. Inc. (NYSE: MRK) |
Expansion of 6/96 research and license agreement to develop anti-infective drugs | ND | Under expanded agreement, Cubist licensed to Merck two chemical classes of novel anti-infective compounds; Cubist received undisclosed payment for license, as well as a payment for achieving a medicinal chemistry milestone (8/99) |
Discovery Therapeutics Inc.* |
Schwarz Pharma (Germany) | Expansion of 1998 agreement for Parkinson Patch (SPM-962) |
5M | Expansion of 1998 development and marketing agreement to include Japan; in connection with the expansion, Schwarz made a $5M equity investment in DTI (12/99) |
Exelixis Pharmaceuticals Inc.* |
Pharmacia & Upjohn (NYSE: PNU) |
Expansion of 3/99 collaboration to use Exelixis' Path-Finder technology to identify targets for small-molecule therapeutics in the areas of Alzheimer's disease and metabolic syndrome |
ND | Companies expanded collaboration to include utilization of technology developed for Exelixis' Mechanism of Action Program (11/99) |
Genome Therapeutics Corp. | Schering-Plough Corp. (NYSE: SGP) |
Extension of 9/97 genomics alliance to discover and develop new drugs to prevent and treat fungal infections | ND | Agreement extended through 9/01 (12/99) |
Genset SA (France) | Genetics Institute (unit of Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products Corp.; NYSE:AHP) |
New gene libraries agreement replaces 8/97 agreement under which Genset provided secreted proteins for use in GI's Discover-Ease library, to which multiple parties have access and licensing options |
ND | Under new agreement, GI gains an in-licensing option on up to 1,000 selected sequences and corresponding clones from Genset's library; Genset could receive milestones and royalties on its proteins that are already included in DiscoverEase (10/99) |
Incyte Pharmaceuticals Inc. | Pfizer Inc. (NYSE:PFE) |
Expansion of relationship dating back to 6/94 for genomic database access |
ND |
Pfizer will provide funding, scientific expertise and priorities for the completion of Incyte's genetic drug target portfolio, which will be licensed broadly to Incyte's LifeSeq Gold subscribers and academic partners (11/99) |
Rhone-Poulenc Rorer (a unit of Rhone-Poulenc SA; France; NYSE:RP) | Expansion of 12/97 agreement for genomic database access |
ND |
Expanded agreement includes access to Incyte's LifeSeq Gold assembled database, the Life-Array expression analysis software, and a collaboration to provide customized bioinformatics solutions for RPR (8/99) | |
Millennium Pharmaceuticals Inc. |
Wyeth-Ayerst Research (pharmaceutical R&D division of American Home Products Corp.; NYSE: AHP) | Extension of 12/96 antibacterials collaboration to identify bacteria-specific small-molecule targets and drug lead candidates |
ND | Companies extended agreement for 2 years; Millennium has delivered 8 antibacterial targets for screening (10/99) |
Myriad Genetics Inc. |
Schering AG (Germany) | Expansion of 10/98 collaboration to use Myriad's ProNet technology to identify genetic drug targets for cancer therapeutics |
$10 |
Collaboration expanded into the heart disease area; Schering Berlin Venture Corp. purchased $10M of Myriad stock at a premium (10/99) |
OSI Pharmaceuticals Inc. |
Sankyo Company Ltd. (Japan) |
Renewal of 3/97 collaboration to discover and develop small-molecule compounds to treat influenza | ND | Companies renewed agreement for an additional 2 years; several active compounds have been identified (11/99) |
Protein Design Labs Inc. | Hoffmann-La Roche Inc. (Switzerland) | Expansion of 10/96 development and marketing agreement for Zenapax (daclizumab), which already is marketed for prevention of kidney transplant rejection | ND | PDL will assume worldwide responsibility for clinical development of Zenapax in auto-immune diseases; in return, PDL will receive a significant share of Zenapax revenues from sales for autoimmune indications, either in the form of sales revenue from PDL marketing the drug itself or revenue sharing with Roche; in the U.S. and Canada, PDL will have ultimate responsibility to market, promote and detail Zenapax in autoimmune indications; in other territories, Roche may elect to market the drug in those indications and pay PDL a substantial portion of revenue; in countries where Roche opts not to market, PDL will receive an exclusive license to market Zenapax and will pay Roche a small royalty (10/99) |
Protein Sciences Corp.* |
Pasteur Merieux Connaught (unit of Rhone-Poulenc SA; France; NYSE:RP) |
Original agreement signed in 1995 for recombinant hemagglutinin influenza vaccine; new agreement provides late-stage terms and separate deal providing option for baculovirus expression vector system (BEVS) |
ND | New flu vaccine agreement sets terms for late-stage development; PMC retains all commercial rights and has the option to take over clinical development; Protein Sciences will receive milestones for preparation of Phase III clinical materials, successful completion of Phase III trials and regulatory approval, and will receive royalties on sales; PMC can exercise the option and make a payment on delivery of Phase III materials; in second deal, PMC gained option for exclusive rights to BEVS for development of subunit vaccines in defined air-borne diseases; development will be funded by PMC, and Protein Sciences will receive royalties on each approved vaccine (11/99) |
Tripos Inc. | Pfizer Inc. (NYSE:PFE) |
Extension of 7/97 sponsored research collaboration to design and develop new software products for pharmaceutical research |
ND | New agreement will focus on developing tools to shorten analysis and compound/library design time in lead optimization projects (8/99) |
Vion Pharmaceuticals Inc. |
Boehringer Ingelheim International GmbH (Germany) |
Restructuring of 10/97 agreement for Promycin, a hypoxic cancer cell therapy in development for head and neck cancer | ND |
Under restructuring agreement, Boehringer will assume full managerial and financial responsibility for development, and Vion will receive reduced milestones and royalties (12/99) |
TERMINATED AGREEMENTS | ||||
Biomatrix Inc. | Rhone-Poulenc Rorer (a unit of Rhone-Poulenc SA; France; NYSE:RP) |
Termination of 9/95 agreement under which Rhone-Poulenc marketed Synvisc in Canada |
ND | Biomatrix's Canadian subsidiary will exclusively market and distribute Synvisc in Canada (11/99) |
Cortecs plc (UK; LSE: CCS) |
TOWA Pharmaceuticals Co. Ltd. (Japan) | Termination of 12/95 agreement for distribution of Macritonin in Japan | £1.6 (US$2.6) |
Cortecs received a £1.6M (US$2.6M)payment (7/99) |
Incara Pharmaceuticals Corp. | BASF Pharma/Knoll AG (Germany) | Termination of 12/96 collaboration to develop Bextra (bucindolol HCl) in territories outside the U.S. and Japan |
ND |
Companies terminated agreement following decision of National Institutes of Health and the Department of Veterans Affairs to terminate Phase III study of Bextra in heart failure patients in the U.S. for lack of a statistically significant survival benefit in a European Phase III trial (8/99) |
IntraBiotics Pharmaceuticals Inc.* |
Pharmacia & Upjohn S.p.A. (unit of Pharmacia & Upjohn; NYSE:PNU) | Termination of 10/97 collaboration to jointly develop Protegrin IB-367 Rinse, a topical antimicrobial, in the U.S. for the treatment and prevention of oral mucositis; P&U also held an exclusive license for all other territories | ND |
IntraBiotics reacquired rights to Protegrin, which has completed Phase II trials and is slated for Phase III testing; companies terminated agree ment (8/99) |
Isis Pharmaceuticals Inc. |
Novartis Pharma AG (Switzerland) |
Termination of 2/96 agreement for the development of ISIS 3521 and ISIS 5132, two anticancer compounds |
ND |
Novartis returned rights following completion of clinical trials; Isis plans to start pivotal trials of ISIS 3521 in non-small-cell lung cancer in mid-2000 (11/99) |
NOTES: | ||||
# This chart does not include any marketing and/or distribution agreements that involve agricultural product development. The information in the chart covers the time period between 11/1/99 and 12/31/99. | ||||
ND = Not disclosed, reported and/or available | ||||
* Private companies are indicated with an asterisk. | ||||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 15-16. | ||||
@ The dates listed are the dates of press releases. They are not necessarily the dates on which transactions took place. | ||||
AMEX = American Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange | ||||
Conversion rate of £1 = US$1.6 | ||||
